OMC
CTMX icon

Oasis Management Company’s CytomX Therapeutics CTMX Stock Holding History

Oasis Management Company’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-540,541
Closed -$865K – 84
2022
Q4 		$865K Hold
540,541
– – 0.17% 51
2022
Q3 		$784K Hold
540,541
– – 0.13% 69
2022
Q2 		$989K Buy
+540,541
New +$1.03M 0.17% 55

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oasis Management Company's CTMX Position: Q1 2023 in Review

Oasis Management Company sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 540,541 shares — an estimated $865K sold.

Oasis Management Company first reported a position in CTMX in Q2 2022 and held it in 3 quarters. The position peaked at $989K in Q2 2022. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

  • Oasis Management Company reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 540,541 CytomX Therapeutics shares in Q1 2023, an estimated $865K.
  • Oasis Management Company first reported a position in CytomX Therapeutics in Q2 2022 and held it in 3 quarters.
  • Oasis Management Company's CytomX Therapeutics position peaked at $989K in Q2 2022.
  • 75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.